Curanex PharmaceuticalsCommon Stock Accounts Payable

Curanex PharmaceuticalsCommon Stock (CURX) currently reports a accounts payable of $150 as of June 2026. That compares with $270 in the prior-year period — down 42.8% year over year. Use the charts on this page to explore Curanex PharmaceuticalsCommon Stock's accounts payable history and peer comparisons.

Curanex PharmaceuticalsCommon Stock's accounts payable decreased from $270 to $150 — a 42.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Curanex PharmaceuticalsCommon Stock reported $150 in accounts payable as of June 2026. That compares with $270 in the prior-year period — down 42.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $150, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Curanex PharmaceuticalsCommon Stock, and consider following CURX for alerts when major investors trade the stock.

Curanex PharmaceuticalsCommon Stock is classified in the Healthcare sector. On accounts payable, it currently shows $150. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CURX with unrelated industries.